Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

Required: CCNE1 overexpression

Cyclin E1 overexpression

Allowed: FOLR1 overexpression

Should have received prior treatment with mirvetuximab soravtansine if the tumor is positive for FRα, unless there is an exception for its use on medical grounds.

Must have received: platinum-based chemotherapy

Have platinum-resistant disease. Participants who have only had 1 line of platinum-based therapy must have received at least 4 cycles of platinum containing regimen. Participants who have received 2 to 4 lines of platinum-based therapy must have progressed on or within 6 months after the last dose of platinum.

Must have received: bevacizumab (bevacizumab)

Should have received prior treatment with bevacizumab unless there was a contraindication for its use.

Must have received: antibody-drug conjugate (mirvetuximab soravtansine)

Should have received prior treatment with mirvetuximab soravtansine if the tumor is positive for FRα, unless there is an exception for its use on medical grounds.

Cannot have received: platinum-based chemotherapy

Exception: primary platinum-refractory disease (progression on or within 3 months after the last dose of first line platinum-containing therapy)

Have primary platinum-refractory disease, defined as progression on or within 3 months after the last dose of first line platinum-containing therapy.